Neoplasms, Hematologic Completed Phase 1 / 2 Trials for Nivolumab (DB09035)

Also known as: Hematological Neoplasm / Hematological Neoplasms / Hematologic Neoplasm / Hematologic Neoplasms / Haematological neoplasm / Malignant tumor of lymphoid hemopoietic and related tissue (disorder) / Haematological malignancy / Hematological malignancy / Hematologic neoplasm (disorder)

IndicationStatusPhase
DBCOND0056760 (Neoplasms, Hematologic)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02329847A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic MalignanciesTreatment
NCT02061761A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell MalignanciesTreatment